delivered the opinion of the Court.
Over the years, our choice-of-law jurisprudence has striven to structure rules that will lead to predictable and uniform results that are fair and just and that will meet the reasonable expectations of the parties. In this appeal, we attempt to advance that goal.
Accutane is a prescription medication for the treatment of severe cases of acne. In this products-liability action filed in New Jersey, plaintiff Andrew McCarrell, an Alabama resident, claims that he developed a virulent form of inflammatory bowel disease as a result of taking Accutane. He also claims that had Accutane’s warning labels adequately informed him of the risks and dangers associated with Accutane, he would not have taken the medication.
Plaintiff was prescribed and took Accutane in Alabama, and he developed and was treated for inflammatory bowel disease in that state. Defendants Hoffmann-La Roche, Inc., and Roche Laboratories, Inc., both New Jersey corporations, (collectively Roche), designed, manufactured, and labeled Accutane in New Jersey and distributed the medication from this State.
*574 Plaintiff timely filed the products-liability action under New Jersey’s statute of limitations, but Alabama’s limitations period had expired by the time of the filing. The issue is which state’s statute of limitations applies under New Jersey’s choice-of-law jurisprudence.
The trial court concluded that under the governmental-interest test articulated in
Gantes v. Kason Corp.,
145
N.J.
478, 484,
The Appellate Division reversed and dismissed the action, finding that Alabama’s statute of limitations governed under the substantial-relationship test in sections 146, 145, and 6 of the Restatement (Second) of Conflicts of Law (1971) (Am. Law Inst., amended 1988) (Restatement (Second)). The American Law Institute crafted that test to determine whether the forum state’s or another state’s substantive law applies in a tort action. That test begins with a presumption favoring the law of the state where the injury occurred.
The American Law Institute, however, fashioned a different test to resolve choice-of-law determinations involving statutes of limitations. Under section 142 of the Second Restatement, the statute of limitations of the forum state—here, New Jersey—applies if that state has a substantial interest in the maintenance of the claim and there are no “exceptional circumstances” that “make such a result unreasonable.”
We hold that section 142 of the Second Restatement is now the operative choice-of-law rule for resolving statute-of-limitations conflicts because it will channel judicial discretion and lead to more predictable and uniform results that are consistent with the just expectations of the parties. The adoption of section 142 is also a natural progression in our conversion from the governmental-interest test to the Second Restatement begun in
P.V. ex rel. T.V. v. Camp Jaycee,
197
N.J.
132,
An analysis under section 142 of the Second Restatement leads to the conclusion that New Jersey’s statute of limitations was properly applied to this products-liability action. Our jurisprudence has long recognized that this State has a substantial interest in deterring its manufacturers from placing dangerous products in the stream of commerce. Inadequate warning labels can render prescription medications dangerous. No exceptional circumstances are present that would render the application of New Jersey’s limitations period unreasonable. Importantly, even were we to apply our previous governmental-interest test, the outcome would be no different.
We therefore reverse and reinstate the jury’s verdict and award. We remand to the Appellate Division for consideration of the unaddressed issues remaining on appeal.
I.
A.
In July 2003, plaintiff filed a products-liability action in the Superior Court, Law Division, alleging that defendant Roehe—the New Jersey manufacturer, marketer, and distributor of Accu-tane—failed to provide adequate warnings about the risks and side effects associated with taking Accutane. Plaintiff asserts that had he received proper warnings about the potentially devastating side effects of Accutane, he would not have taken the medication, which he claims was the proximate cause of his inflammatory bowel disease. Plaintiff also alleges that Roche’s mislabeling of Accutane violated the New Jersey Consumer Fraud Act, N.J.S.A. 56:8-1 to -20.
The sole issue before us is whether the statute of limitations of New Jersey (the forum state) or Alabama (the injury-site state) *576 governs this ease. From the voluminous trial and pre-trial record, we recite the facts relevant to address that issue.
B.
Plaintiff, a resident of Alabama, had suffered from acne since high school, and antibiotics proved to be an ineffective treatment. In June 1995, when plaintiff was twenty-four years old, his dermatologist prescribed Accutane. Plaintiff took daily doses of the medicine for the next four months. Four weeks into the treatment program, plaintiff experienced dry eyes, achy joints, and chapped lips but complained of no other adverse side effects. After completing his regimen of Accutane, plaintiff noticed that his skin was clearer. At a four-month posU-Accutane review with his dermatologist in February 1996, plaintiff reported that the prior side effects had subsided and that he had experienced no new health problems.
In August 1996, ten months after he stopped taking Accutane, plaintiff began experiencing intense stomach pain and diarrhea. Over the next several months, plaintiffs condition worsened, and his primary care physician referred him to a gastroenterologist. In November 1996, plaintiff was diagnosed as suffering from inflammatory bowel disease. By the next month, as a result of constant bleeding from the rectum, plaintiff became anemic. Plaintiffs weight had dropped from 162 pounds, his pre-Accutane weight, to just 114 pounds at this point.
Over the next several years, plaintiff underwent multiple surgeries. Plaintiffs colon and rectum were removed and replaced with a j-pouch—an artificially constructed reservoir at the end of the small intestines—that is intended to allow for ordinary bowel movements. The j-pouch became inflamed, causing plaintiff to suffer persistent and severe gastrointestinal pain and flu-like symptoms. To permit the j-pouch to heal, a colostomy bag was attached to plaintiffs small intestine through a surgical procedure. Plaintiff subsisted with the colostomy bag for four-and-one-half years until another surgery reconnected the j-pouch to the small *577 intestine. Plaintiff continues to suffer from severe abdominal cramping, multiple bowel movements every day, and episodes of incontinence.
Plaintiff was prescribed and took Accutane in Alabama and was treated for the medical complications related to inflammatory bowel disease in that state.
C.
Defendants Hoffmann-La Roche, Inc., and Roche Laboratories, Inc., were incorporated in New Jersey and maintained their corporate offices here. They designed, manufactured, and labeled Accutane in New Jersey and distributed the product from this State.
In 1982, the United States Food and Drug Administration approved Accutane, known generically as isotretinoin, for the treatment of recalcitrant nodular acne. At the time that plaintiffs physician prescribed, and plaintiff took, Accutane, Roche had provided various warnings about Accutane’s possible adverse side effects—including potential gastrointestinal disorders—by means of product labeling, a patient brochure, and a Dear Doctor letter. 1
Plaintiff claims that the Accutane label and other warnings conveyed the impression that the listed adverse reactions to Accutane would arise while the patient was taking the medication and that discontinuing its use would resolve such problems. Plaintiff also contends that the warnings did not suggest that he could develop an irreversible case of inflammatory bowel disease after completion of the Accutane regimen. He asserts that, during the period he took Accutane, Roche knew or should have known that Accutane not only could trigger inflammatory bowel disease after its use, but that it also could cause irreversible damage to his *578 organs, and that Roche failed to provide adequate warnings to him and his physician about those risks.
Roche counters that the warnings sufficiently apprised defendant of the associated risks of taking Accutane and that plaintiffs use of the medication was not the proximate cause of his inflammatory bowel disease.
D.
Roche moved for summary judgment to dismiss plaintiffs claims on the basis that they were barred by Alabama’s two-year statute of limitations governing personal injury claims.
See Ala. Code
§ 6-2-38©. Roche reasoned that because plaintiffs injury occurred in 1996 and his claim was filed in 2003, the claim was not filed within the appropriate limitations period. In contrast, plaintiff argued that the equitable “discovery rule” incorporated into New Jersey’s two-year statute of limitations,
N.J.S.A.
2A:14-2, was the applicable law. Under the “discovery rule,” the statute of limitations does not begin to run “until the injured party discovers, or by an exercise of reasonable diligence and intelligence should have discovered that he may have a basis for an actionable claim.”
Lopez v. Swyer,
62
N.J.
267, 272,
The Honorable Carol Higbee, J.S.C., who presided over the case, denied Roche’s motion. Judge Higbee stated that the governmental-interest test, as expounded in
Gantes, supra,
145
N.J.
at 484,
*579 Judge Higbee determined that plaintiff did not become aware that his use of Accutane could have caused his inflammatory bowel disease until June 2003. Because plaintiff filed his complaint six weeks after that discovery, Judge Higbee concluded that, under New Jersey’s equitable tolling rule, the complaint was timely filed.
E.
At the conclusion of a four-week jury trial in 2007, the court instructed the jury on Alabama’s substantive law, including its products-liability law. 2 The jury found in favor of plaintiff on the failure-to-warn claim and awarded damages in the amount of $2,619,000. The jury rejected plaintiffs consumer-fraud claim.
The Appellate Division reversed the jury’s failure-to-warn verdict based on erroneous evidentiary rulings by the trial court and remanded for a new trial. The Appellate Division, however, approved of the trial court’s “sound” reasoning in finding that “the competing policy interests at stake” called for the application of New Jersey’s statute of limitations on the failure-to-warn claim. The Appellate Division also concluded that the trial court “had ample factual grounds to find that [New Jersey’s] two-year limitation period should be equitably tolled to accommodate plaintiffs lawsuit.”
We denied Roche’s petition for certification.
McCarrell v. Hoffmann-La Roche, Inc.,
199
N.J.
518,
F.
Plaintiffs second trial in 2010 lasted about four weeks. The jury found Roche liable on plaintiffs failure-to-warn claim and awarded plaintiff $25,159,530. Roche moved for a judgment notwithstanding the verdict, arguing again that the trial court erroneously applied New Jersey’s limitations period. Relying on
Camp Jaycee, supra,
*580
197
N.J.
132,
Judge Higbee denied the motion, holding that Roche’s change-of-law argument was not timely because Roche did not argue for adoption of those sections of the Second Restatement when it appeared before the Appellate Division, despite the availability of the Camp Jaycee decision. 3 Judge Higbee, moreover, concluded that the decision to apply the New Jersey limitations period would be no different if she were to engage in an analysis under Second Restatement sections 146,145, and 6.
G.
In an unpublished opinion, an appellate panel accepted Roche’s change-of-law argument—the argument that Camp Jaycee altered the landscape—and held that Alabama’s two-year statute of limitations governed under sections 146, 145, and 6 of the Second Restatement. It noted that plaintiff received his inflammatory bowel disease diagnosis on November 26, 1996, but did hot file his claims until July 23, 2003. Because Alabama’s statute had no equitable tolling provision, the panel vacated the jury’s verdict and award and dismissed plaintiffs complaint as having been filed out of time.
The panel held that under section 146 of the Second Restatement, “the law of the state where the injury occurred”—here,
*581
Alabama—applies “unless another state has a more significant relationship to the issue” based on an analysis of the factors enumerated in Second Restatement sections 145 and 6. After analyzing those factors, the panel concluded that the injury-site presumption had not been overcome. It focused on the fact that Alabama is where plaintiff resided, where he was prescribed and took Accutane, and where he developed and was treated for inflammatory bowel disease. The panel took the view that “New Jersey has little interest in protecting the compensation right of [an out-of-state] resident,” quoting
Cornett, supra,
414
N.J.Super.
at 381,
The panel expressly declined to apply section 142 of the Second Restatement—a section specifically crafted to resolve the choice-of-law issue that arises when the forum state’s and another state’s statutes of limitations are in conflict. Under section 142, the limitations period of the forum state applies unless it has “no substantial interest” in maintaining the claim in its courts.
The panel did not reach the remaining issues raised by Roche on appeal. 4
We granted plaintiffs petition for certification.
McCarrell v. Hoffmann-La Roche, Inc.,
223
N.J.
555,
II.
A.
Plaintiff argues that the Appellate Division erred by not applying section 142 of the Second Restatement, entitled “Statute of *582 Limitations of Forum.” That section, he notes, is specifically designed to decide choice-of-law questions governing the timeliness of a tort action when two or more interested states have conflicting statutes of limitations.
Plaintiff asserts that had the appellate panel in this case applied section 142 and its presumption favoring the forum state’s statute of limitations, it would have upheld the trial court’s finding that this State’s limitations period applies. Plaintiff further maintains that, even if Restatement sections 146, 145, and 6 govern, along with the presumption favoring the injury-site state, a proper weighing of the factors would indicate that New Jersey, not Alabama, has the “most significant relationship” to this produets-liability action. Under either analysis, plaintiff submits, New Jersey’s statute of limitations applies.
Amicus New Jersey Association for Justice urges this Court to adopt section 142 of the Second Restatement, reasoning that 142’s presumption favoring the forum state’s statute of limitations will allow for more uniform and predictable choice-of-law decision-making and advance New Jersey’s strong interest in regulating its manufacturers.
B.
Roche argues that the proper choice-of-law analysis for determining the applicable statute of limitations is set forth in sections 146, 145, and 6 of the Second Restatement. Roche submits that viewing New Jersey’s and Alabama’s respective interests through the lens of those Restatement sections leads to the conclusion that plaintiff did not overcome the presumption favoring use of the injury-site state’s statute of limitations. Roche therefore asserts that the Appellate Division correctly dismissed plaintiffs action under Alabama’s limitations period.
Roche asserts that plaintiff—by advancing section 142 as the governing choice-of-law modality—is attempting to revive the now-defunct common-law rule that the forum state’s statute of limitations prevails as a matter of procedure. That approach,
*583
Roche insists, was rejected by this Court in
Heavner v. Uniroyal, Inc.,
63
N.J.
130,
Roche further asserts that, even if this Court were to apply section 142 to the choice-of-law issue in this ease, the outcome would be no different; Alabama’s statute of limitations would govern because nearly all of the significant events related to this litigation occurred in Alabama.
Amicus New Jersey Civil Justice Institute also asks this Court to reject plaintiffs invitation to adopt section 142 of the Second Restatement. The Civil Justice Institute expresses concern that ratifying section 142’s framework will encourage forum shopping by out-of-state residents seeking to sue New Jersey pharmaceutical companies in our courts.
III.
When a civil action is brought in New Jersey, our courts apply New Jersey’s choice-of-law rules in deciding whether this State’s or another state’s statute of limitations governs the matter.
Gantes, supra,
145
N.J.
at 484,
The analytical framework for deciding how to resolve a choice-of-law issue is a matter of law.
See Mastondrea v. Occidental Hotels Mgmt. S.A.,
391
N.J.Super.
261, 283,
We begin with a brief discussion of some general choice-of-law principles governing statutes of limitations.
A.
The first inquiry in any choice-of-law analysis is whether the laws of the states with interests in the litigation are in conflict.
Gantes, supra,
145
N.J.
at 484,
The history of our evolving choice-of-law jurisprudence will provide context to the issue before us.
B.
Under the common law, the forum state—the state in which a lawsuit was filed—applied its own statute of limitations when a choice-of-law issue arose.
See, e.g., Smith v. Smith,
90
N.J.L.
282, 286-87, 101 A 254 (E. & A. 1917) (“A foreign judgment is subject to the statute of limitations of the
lex fori[,J ...
the law of the place where the action is instituted.” (citation omitted)). That approach was based on the common-law notion that statutes of
*585
limitations are “procedural in nature and therefore subject to the law of the forum.”
Marshall v. Geo. M. Brewster & Son, Inc.,
37
N.J.
176, 180,
In
Heavner v. Uniroyal, Inc.,
we rejected the inflexible common-law rule of always applying our own statute of limitations in choice-of-law matters merely because limitations periods were denominated as procedural. 63
N.J.
130, 140-41,
Heavner
involved a products-liability action brought in New Jersey. The plaintiff, a North Carolina resident, was driving a truck purchased in North Carolina when the truck’s tire blew out, causing an accident in North Carolina.
Id.
at 133-34,
We found that the only connection between New Jersey and the products-liability action was Uniroyal’s incorporation in this State.
Id.
at 134 n.3,
Importantly, we stressed that our ruling was limited to the “factual pattern” in Heavner and that “there may well be situations involving significant interests of this state where it would be inequitable or unjust to apply the concept we here espouse.” 7 Id. at 141, 305 A 2d 412.
In
Gantes v. Kason Corp.,
145
N.J.
478,
Gantes
involved a Georgia resident who died as a result of an allegedly defective moving part in a Georgia processing plant.
Id.
at 481-82,
The obvious conflict between New Jersey’s and Georgia’s limitations periods required an analysis of the two states’ interests in resolving the dispute.
Ibid.
In assessing Georgia’s interests, the Court observed that Georgia’s legislature enacted its ten-year statute of repose “to eliminate stale claims and stabilize products liability underwriting.”
Id.
at 486,
In evaluating New Jersey’s governmental interests, the Court recognized this State’s “strong interest in encouraging the manufacture and distribution of safe products for the public and, conversely, in deterring the manufacture and distribution of unsafe products within the state.”
Id.
at 490,
Accordingly, our Court applied New Jersey’s limitations period and permitted the wrongful death lawsuit to proceed.
Id.
at 499,
C.
This Court had adopted the governmental-interest test to resolve choice-of-law issues concerning substantive tort law before
Heavner
and
Gantes
adopted that test for statutes of limitations.
See Mellk, supra,
49
N.J.
at 234-35,
The governmental-interest test remained the analytical tool for deciding choice-of-law issues related to substantive tort law and statutes of limitations until
P.V. ex rel. T.V. v. Camp Jaycee,
197
N.J.
132,
We noted, generally, in
Camp Jaycee
that one of the benefits of the Second Restatement is the use of
“presumptions
and detailed considerations that bear on conflicts analyses” in deciding choice of law.
Id.
at 140,
In
Camp Jaycee, supra,
we held that in a personal-injury action, the substantive law of the place of injury is presumed to be the governing law under section 146.197
N.J.
at 141,
The
Camp Jaycee
Court was well aware that the Second Restatement had crafted different presumptions to apply in various other scenarios.
See id.
at 140-41,
In
Cornett v. Johnson & Johnson,
211
N.J.
362,
D.
Camp Jaycee’s
adoption of sections 146, 145, and 6 of the Second Restatement to resolve conflicts of substantive law in tort actions with an injury-site presumption was not a signal that we would apply the same choice-of-law test for statutes of limitations. Indeed, the drafters of the Second Restatement did not intend that sections 146 and 145 would be used for statute-of-limitations choice-of-law determinations. That is so because the American Law Institute crafted section 142 of the Second Restatement precisely to address statutes of limitations as an independent issue for choice-of-law purposes. The rationales for whether the forum
*592
state’s substantive law or statute of limitations should govern are different. That was evident in
Gantes, supra,
where Georgia’s products-liability law governed, but New Jersey’s statute of limitations applied. 145
N.J.
at 492-93,495-96,
The essential purpose of substantive tort law is to provide a remedy to a party who has been wronged, see
Fu v. Fu,
160
N.J.
108, 123,
There are strong policy reasons for this Court to adopt section 142 as the choice-of-law rule for statutes of limitations. Incorporating section 142 into our choice-of-law analysis for tort purposes completes the conversion from the governmental-interest standard to the Second Restatement begun in Camp Jaycee.
We therefore turn to a discussion of section 142 of the Second Restatement.
E.
The Second Restatement recognizes that when the forum state has a substantial interest in litigation brought in its courts, the forum state’s statute of limitations, ordinarily, will apply. Section 142 provides:
Whether a claim will be maintained against the defense of the statute of limitations is determined under the principles stated in § 6. In general, unless the exceptional circumstances of the case make such a result unreasonable:
(1) The forum will apply its own statute of limitations barring the claim.
(2) The forum will apply its own statute of limitations permitting the claim unless:
(a) maintenance of the claim would serve no substantial interest of the forum; and
(b) the claim would be barred under the statute of limitations of a state having a more significant relationship to the parties and the occurrence.
[Restatement (Second), supra, § 142.]
*593 Section 142⅛ presumption, like other presumptions in the Second Restatement, channels judicial discretion and advances notions of uniformity and predictability. Under section 142(2)(a), the statute of limitations of the forum state generally applies whenever that state has a substantial interest in the maintenance of the claim. See Restatement (Second), supra, § 142(2). In that circumstance, the inquiry ends for statute-of-limitations purposes, unless exceptional circumstances would render that result unreasonable. Restatement (Second), supra, § 142. Only when the forum state has “no substantial interest” in the maintenance of the claim does a court consider section 142(2)(b)—whether “the claim would be barred under the statute of limitations of a state having a more significant relationship to the parties and the occurrence.” Restatement (Second), supra, § 142(2)(a)-(b). In determining whether another state has a more significant relationship to the parties and the occurrence, a court must then consider overarching choice-of-law principles embodied in the factors in section 6:
(a) the needs of the interstate and international systems,
(b) the relevant policies of the forum,
(c) the relevant policies of other interested states and the relative interests of those states in the determination of the particular issue,
(d) the protection of justified expectations,
(e) the basic policies underlying the particular field of law,
(f) certainty, predictability and uniformity of result, and
(g) ease in the determination and application of the law to be applied.
[.Restatement (Second), supra, § 6(2).]
Section 142 benefits from an ease of application; places both this State’s and out-of-state’s citizens on an equal playing field, thus promoting principles of comity; advances predictability and uniformity in decision-making; and allows for greater certainty in the expectations of the parties.
Second Restatement section 142 makes clear that when New Jersey has a substantial interest in the litigation and is the forum state, it will generally apply its statute of limitations.
See Restatement (Second), supra,
§ 142(2). That rule is consistent with our holding in
Gantes, supra,
in which we allowed an out-of-state
*594
citizen to pursue a products-liability action against a New Jersey manufacturer in our state courts because of New Jersey’s substantial interest in ensuring the manufacture and distribution of safe products. 145
N.J.
at 490,
This rule also benefits New Jersey companies. Under the Appellate Division’s application of Second Restatement sections 146 and 145, the statute of limitations of the state where the injury occurred would presumptively apply even when the New Jersey limitations period had expired. In that circumstance, the out-of-state citizen could proceed with a claim when a New Jersey resident could not if the injury had occurred in this State. That deprives New Jersey companies of the protections of this State’s statute of limitations against another state’s longer limitations period.
A New Jersey company, generally, should not have to defend against a claim that is stale under this State’s statute of limitations in our courts, whether that claim is brought by a New Jersey resident or a citizen of another state. When a plaintiff from another state with a longer limitations period seeks to press a claim against a New Jersey manufacturer in our state courts after New Jersey’s statute of limitations has expired, section 142 ordinarily will not permit the claim to proceed. See Restatement (Second), supra, § 142(1) (stating that absent “exceptional circumstances” that would make result “unreasonable,” “[t]he forum will apply its own statute of limitations barring the claim”). Moreover, when New Jersey has no substantial interest in the litigation, under section 142, our courts will not apply our State’s statute of limitations to save a claim when another state has a more significant relationship to the case. See Restatement (Second), supra, § 142(2).
*595
Pitcock v. Kasowitz, Benson, Torres & Friedman, LLP,
426
N.J.Super.
582,
In light of Camp Jaycee ⅛ adoption of the Second Restatement to resolve substantive tort law conflicts, the appellate panel predicted that this Court would “apply the ‘most significant relationship’ test of section 142 in determining the applicable statute of limitations” in tort cases. Id. at 589, 46 A 3d 586. Although the plaintiff was a New Jersey resident, the firm’s primary office was in New York, where the plaintiff worked. Id. at 584, 46 A3d 586. Previously, the firm had filed an action in New York Supreme Court claiming that the plaintiff breached contractual and fiduciary duties based on his allegedly improper conduct in New York. Ibid. The firm’s New York claim ultimately was dismissed, which led to the malicious-abuse-of-process lawsuit filed by the plaintiff in New Jersey. Id. at 584-85, 46 A3d 586.
In an opinion authored by Judge Skillman, the panel concluded that New Jersey did not have a substantial interest in “protecting its residents from financial harm arising from their professional activities in another state” and that New York “clearly ha[d] ‘a more significant relationship to the parties and the occurrence’ than New Jersey.”
Id.
at 589-90,
We agree that the results in Heavner and Gantes would be no different under a Second Restatement section 142 analysis *596 than the actual results reached by the Court in those cases using the governmental-interest test. But there are meaningful distinctions between section 142 and the governmental-interest test. Section 142’s presumption in favor of a forum state with a substantial interest in the litigation can be overcome only by exceptional circumstances that would render that result unreasonable. Under the governmental-interest test, a forum state’s substantial interest in the litigation is a significant factor—but not a conclusive one— to be weighed against the interests of another state connected with the parties or the occurrence. Section 142 is a less malleable standard than the governmental-interest test. For all practical purposes, under section 142, once a court finds that the forum state has a substantial interest in the litigation, the inquiry is at an end.
It bears mentioning, however, that, under both tests, when the forum state has
no interest
in the litigation and the claim is barred by another state’s statute of limitations, the forum state generally should not entertain the claim.
Restatement (Second), supra,
§ 142 cmt. g;
see also Heavner, supra,
63
N.J.
at 134 n.3,141,
We are persuaded that section 142, with its presumption favoring a forum state with a substantial interest in the matter, will channel judicial discretion to ensure a higher degree of uniformity and predictability in resolving choice-of-law issues.
We now apply the principles of section 142 to the facts of this case.
TV.
In this failure-to-warn products-liability action filed in New Jersey, plaintiff presented evidence that (1) defendants Hoff-mann-La Roche, Inc., and Roche Laboratories, Inc., were New Jersey corporations, which maintained their corporate offices in *597 this State; (2) defendants designed, manufactured, distributed, and labeled the prescription drug Accutane in New Jersey; (3) defendants’ labeling inadequately warned plaintiff of the potential risks associated with the taking of Accutane; (4) plaintiff, an Alabama resident, relied on the inadequate warnings when his physician prescribed, and he took, Accutane to treat his acne in Alabama; and (5) the taking of Accutane proximately caused his inflammatory bowel disease, which led to multiple surgeries and other treatment modalities in Alabama.
Under section 142 of the Second Restatement, New Jersey, as the forum state, presumptively applies its own statute of limitations unless (1) New Jersey has no significant interest in the maintenance of the claim and Alabama, whose statute has expired, has “a more significant relationship to the parties and the occurrence,” Restatement (Second), supra, § 142(2)(a)-(b); or (2) given “the exceptional circumstances of the case,” following the Second Restatement rule would lead to an unreasonable result, Restatement (Second), supra, § 142. In light of section 142, if New Jersey has a substantial interest in the litigation, the inquiry ends, and New Jersey applies its statute of limitations, provided there are no “exceptional circumstances” making that “result unreasonable.” Restatement (Second), supra, § 142. Therefore, we first turn to whether New Jersey has a significant interest in the products-liability claim filed by plaintiff against Roche.
New Jersey has a substantial interest in deterring its manufacturers from developing, making, and distributing unsafe products, including inadequately labeled prescription drugs.
See Gantes, supra,
145
N.J.
at 490,
Only if we found that New Jersey had “no substantial interest” would we address the second issue, which is whether “the claim would be barred under the statute of limitations of a state having a more significant relationship to the parties and the occurrence.” Restatement (Second), supra, § 142(2)(a)-(b). Were we to address that issue, we would recognize that Alabama has a significant relationship to the parties and the occurrence. But, even in light of the section 6 factors, it would not be self-evident that Alabama has a more significant relationship than that of New Jersey. See Restatement (Second), supra, § 6(2)(a)-(g).
Clearly, Alabama has a substantial interest in ensuring that pharmaceutical products entering its borders are safe for use by its citizens.
See Casrell v. Altec Indus., Inc.,
Last, the Second Restatement provides that, even when the forum state’s statute of limitations would apply under a section 142(a) and (b) analysis, the Court retains a small window of discretion to override that outcome. Restatement (Second), supra, § 142. A court is not required to apply the forum state’s limitations period if there are “exceptional circumstances” that will “make such a result unreasonable.” Ibid. In this case, no such “exceptional circumstances” are present.
In summary, New Jersey’s statute of limitations governs because we cannot conclude that “maintenance of the claim would serve no substantial interest” of this State and because there are no “exceptional circumstances” that call for the application of Alabama’s limitations period. Restatement (Second), supra, § 142(2)(a).
Although we are adopting a different choice-of-law framework for determining whether the forum state’s or another state’s statute of limitations will apply, had we conducted a governmental-interest test, the result here would be no different—New Jersey’s statute of limitations would govern. We nevertheless believe that our adoption of section 142 is a further refinement of our choice-of-law jurisprudence that will guide judicial discretion toward more predictable and just outcomes.
V.
For the reasons expressed, we reverse the judgment of the Appellate Division, which dismissed plaintiffs verdict and damages award and extinguished his cause of action because the Alabama statute of limitations had expired. We hold that, based on a choice-of-law analysis under section 142 of the Second Restatement, New Jersey’s limitations period governs, and therefore plaintiffs action was timely filed. We also note that the trial court arrived at the same outcome using the then-prevailing governmental-interest test. We therefore reinstate plaintiffs verdict and damages award *600 and remand to the Appellate Division for consideration of the unaddressed issues remaining on appeal.
Notes
A "Dear Doctor letter" is a letter sent to physicians and other health-care professionals by a drug manufacturer or the Food and Drug Administration advising of substantial new warning information.
PLTVA, Inc. v. Mensing,
564
U.S.
604, 615, 131
S.Ct.
2567, 2576,
Neither party contests in the present appeal that Alabama's products-liability law governs this case.
Camp Jaycee was decided six days before oral argument in the Appellate Division and three-and-one-half months before the Appellate Division rendered its decision.
Roche also claimed that the trial court erred in limiting defendant from calling certain expert witnesses; in allowing the case to be submitted to the jury in the absence of sufficient evidence establishing proximate causation; and in not granting a new trial or, alternatively, a remittitur because of the excessiveness of the damages award.
Indeed, the 1971 version of Second Restatement section 142 adhered to this common-law approach. The original version of section 142 instructed that "[a]n action will not be maintained if it is barred by the statute of limitations of the forum” and that "[a]n action will be maintained if it is not barred by the statute of limitations of the forum, even though it would be barred by the statute of limitations of another state." Restatement (Second) of Conflicts of Law § 142 (Am. Law Inst. 1971) (emphasis added). In light of evolving choice-of-law jurisprudence and scholarship, the American Law Institute revised section 142 in 1988, reframing it to include a rebuttable presumption favoring the forum state. Restatement (Second) of Conflicts of Law § 142 (1971) (Am. Law Inst., amended 1988).
By this time, this Court had also abandoned the
lex loci delicti
approach to resolve conflicts of substantive law, instead favoring the governmental-interest analysis.
See Melik v. Sarahson,
49
N.J.
226, 234-35,
The
Heavner
Court specifically cited
Marshall v. Geo. M. Brewster & Son, Inc.
as one example in which New Jersey's "significant interests" would warrant application of New Jersey's statute of limitations, though noting that that case was affirmed using New Jersey's old common-law procedural approach.
Heav-ner, supra,
63
N.J.
at 141 n.6,
The section 145 factors are: "(a) the place where the injury occurred, (b) the place where the conduct causing the injury occurred, (c) the domicil, residence, nationality, place of incorporation and place of business of the parties, and (d) the place where the relationship, if any, between the parties is centered.”
*591
Restatement (Second), supra,
§ 145. The section 6 factors are listed
infra
at 593,
In
Cornett,
the plaintiffs' lawsuit expired under Kentucky's one-year statute of limitations, despite its equitable tolling provision, whereas the lawsuit was viable under New Jersey's two-year statute and its equitable discovery rule.
Cornett, supra,
211
N.J.
at 374, 377-78,
